TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 34155637
Drug: Behavior therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Behavior therapy (8 sessions)
Study: 34155637
Drug: Wait list
Approvals — FDA: no, EMA: no, PMDA: no
Description: Wait list control (8 sessions of behavior therapy after wait list)
Study: 34196442
Drug: Tapentadol (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tapentadol (50 mg extended release)
Study: 34196442
Drug: Oxycodone (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxycodone (10 mg extended release)
Study: 37702920
Drug: Sotrovimab 500
Normalized name: sotrovimab 500 MG in 8 ML Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sotrovimab 500 mg
Study: 34953520
Drug: BRII-196 plus
Normalized name: pectin
DrugBank: Pectin (DB11158)
Approvals — FDA: no, EMA: no, PMDA: no
Description: BRII-196 plus BRII-198 (1000 mg each)
Study: 33319566
Drug: Ganoderma lucidum
Normalized name: GANODERMA LUCIDUM STEM
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ganoderma lucidum (GL) 6 g/day for 6 weeks
Study: 33319566
Drug: Ceratonia siliqua
Normalized name: CERATONIA SILIQUA WHOLE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ceratonia siliqua (CS) 6 g/day for 6 weeks
Study: 34644395
Drug: Post-treatment MRI
Normalized name: hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Post-treatment MRI showing 100% fibrotic fistula
Study: 34644395
Drug: Post-treatment MRI
Normalized name: hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Post-treatment MRI MAGNIFI-CD index
Study: 34644395
Drug: Degree of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Degree of fibrosis at post-treatment MRI
Study: 34644395
Drug: MAGNIFI-CD index
Normalized name: INSULIN MAGNIFIER
Approvals — FDA: no, EMA: no, PMDA: no
Description: MAGNIFI-CD index at post-treatment MRI
Study: 34047292
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (without root canal preparation).
Study: 33823815
Drug: Oral intake
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral intake of 300 ml carbohydrate solution (CH group)
Study: 33823815
Drug: Oral intake
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral intake of 300 ml pure water (PW group)
Study: 36345697
Drug: Hydroquinone 2%
Normalized name: HYDROQUINONE 2% CREAM
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydroquinone 2% cream + 755-nm picosecond laser
Study: 36345697
Drug: Hydroquinone 2%
Normalized name: HYDROQUINONE 2% CREAM
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydroquinone 2% cream alone
Study: 34610971
Drug: Doxorubicin 50
Normalized name: DOXOrubicin 50 mg intravenous powder for injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doxorubicin 50 mg/m2 and lurbinectedin 3.0-5.0 mg (escalation phase)
Study: 34610971
Drug: Doxorubicin 40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doxorubicin 40 mg/m2 and lurbinectedin 2.0 mg/m2 (expansion cohort)
Study: 34429127
Drug: Aspirin, orally,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin, orally, 85-150 mg daily for 35 days after HA and 14 days after KA
Study: 34429127
Drug: Low molecular
Normalized name: Low molecular weight heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low molecular weight heparin (LMWH, enoxaparin), 40 mg, subcutaneously, daily within 24 hours postoperatively for 35 days after HA and 14 days after KA
Study: 32776763
Drug: Physical therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Physical therapy (superficial heat, transcutaneous electrical nerve stimulation, pulsed ultrasound)
Study: 32776763
Drug: Botulinum neurotoxin
Normalized name: Botulinum neurotoxin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Botulinum neurotoxin type A (single intra-articular injection)
Study: 32776763
Drug: Hyaluronic acid
Normalized name: hyaluronic acid
DrugBank: Hyaluronic acid (non-animal stabilized) (DB19175)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hyaluronic acid (three intra-articular injections)
Study: 32776763
Drug: 20% dextrose
Normalized name: Aminosyn II 4.25% in 20% Dextrose
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20% dextrose (three intra-articular injections)
Study: 35640598
Drug: High Brazilian
Normalized name: BRAZILIAN PEPPER
Approvals — FDA: no, EMA: no, PMDA: no
Description: High Brazilian green propolis dose (H‐BGP)
Study: 35640598
Drug: Low Brazilian
Normalized name: BRAZILIAN PEPPER
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low Brazilian green propolis dose
Study: 32105342
Drug: Total magnesium
Normalized name: Colgate Total Mouthwash
Approvals — FDA: no, EMA: no, PMDA: no
Description: Total magnesium intake (diet + supplements)
Study: 34259406
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group received comprehensive therapy of eye covering of intact side and family refined performance
Study: 34916319
Drug: Psychotropic medication
Approvals — FDA: no, EMA: no, PMDA: no
Description: Psychotropic medication use
Study: 33106696
Drug: Oral care
Normalized name: Oral Care Q4 Kit KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral care
Study: 35964471
Drug: Nivolumab 3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nivolumab 3 mg/kg every 2 weeks for 4 doses and then every 12 weeks, intravenously ≤1 year
Study: 35964471
Drug: Ipilimumab 10
Normalized name: Ipilimumab
DrugBank: Ipilimumab (DB06186)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Ipilimumab 10 mg/kg every 3 weeks for 4 doses and then every 12 weeks, intravenously ≤1 year
Study: 32554837
Drug: Qurs-e-Gulnar, 3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Qurs-e-Gulnar, 3 Qurs twice a day for 45 days
Study: 32554837
Drug: Diabeat®, 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diabeat®, 2 capsules twice a day for 45 days
Study: 32867965
Drug: FSE diet
Normalized name: phentermine hydrochloride Oral Capsule [T-Diet]
Approvals — FDA: no, EMA: no, PMDA: no
Description: FSE diet (basal diet + 100 mg/kg FSE)
Study: 32217275
Drug: Sham treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sham treatment and home exercise program (HEP)
Study: 33726537
Drug: Topical Nepafenac
Normalized name: Nepafenac
DrugBank: Nepafenac (DB06802)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Topical Nepafenac
Study: 36332827
Drug: Psilocybin (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Psilocybin (25 mg/70 kg)
Study: 36332827
Drug: Active placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active placebo (50 mg diphenhydramine)
Study: 35794485
Drug: Synergistic mindsets
Approvals — FDA: no, EMA: no, PMDA: no
Description: Synergistic mindsets intervention (self-administered online training module)
Study: 36652353
Drug: BNT162b2 (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: BNT162b2 (30 μg)
Study: 36399969
Drug: Half-dose mRNA-1273
Normalized name: MRNA-1273 SARS-COV-2
DrugBank: Moderna COVID-19 Vaccine (DB15654)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Half-dose mRNA-1273 (50 μg)
Study: 36376733
Drug: mRNA-1273 (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: mRNA-1273 (100 μg)
Study: 36399969
Drug: MVC-COV1901 (15
Approvals — FDA: no, EMA: no, PMDA: no
Description: MVC-COV1901 (15 μg)
Study: 36399969
Drug: All booster
Normalized name: All Clear
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All booster vaccines
Study: 38012751
Drug: mRNA vaccines
Normalized name: ChulaCov19 mRNA vaccine
DrugBank: ChulaCov19 mRNA vaccine (DB16445)
Approvals — FDA: no, EMA: no, PMDA: no
Description: mRNA vaccines
Study: 32273122
Drug: Stick™ resin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Stick™ resin treatment
Study: 32273122
Drug: Ethylene glycol
Normalized name: ethylene glycol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ethylene glycol + triazabicyclodecene treatment
Study: 32336148
Drug: AbobotulinumtoxinA (⩽5
Approvals — FDA: no, EMA: no, PMDA: no
Description: AbobotulinumtoxinA (⩽5 treatment cycles) in the upper limb
Study: 32336148
Drug: AbobotulinumtoxinA (⩽5
Approvals — FDA: no, EMA: no, PMDA: no
Description: AbobotulinumtoxinA (⩽5 treatment cycles) in the lower limb
Study: 32336148
Drug: AbobotulinumtoxinA (⩽5
Approvals — FDA: no, EMA: no, PMDA: no
Description: AbobotulinumtoxinA (⩽5 treatment cycles)
Study: 32339253
Drug: Paclitaxel (80
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paclitaxel (80 mg/m2 on day 1, 8, and 15) plus everolimus (10 mg daily, arm B)
Study: 32339253
Drug: Paclitaxel (80
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paclitaxel (80 mg/m2) plus everolimus (10 mg daily) in patients with prior taxane use
Study: 33206309
Drug: Systemic therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Systemic therapy (ST) after RT (n = 999)
Study: 33206309
Drug: Targeted therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Targeted therapy after RT
Study: 33206309
Drug: Hormone therapy
Normalized name: INVESTIGATIONAL HORMONE THERAPY/REPLACEMENT,OTHER
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hormone therapy after RT
Study: 33206309
Drug: Cytotoxic chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cytotoxic chemotherapy after RT
Study: 33206309
Drug: Immunotherapy after
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immunotherapy after RT
Study: 33206309
Drug: Discontinuation of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Discontinuation of ST after RT
Study: 34387964
Drug: Paracetamol +
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paracetamol + Ibuprofen (PCM + IBU)
Study: 34387964
Drug: Paracetamol (PCM)
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Paracetamol (PCM)
Study: 34387964
Drug: Half Strength-Paracetamol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Half Strength-Paracetamol + Ibuprofen (HS-PCM + IBU)
Study: 34387964
Drug: Non-opioid analgesics
Normalized name: Non-opioid analgesics
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-opioid analgesics before surgery
Study: 34387964
Drug: No analgesics
Normalized name: Analgesic Balm GRX
Approvals — FDA: no, EMA: no, PMDA: no
Description: No analgesics before surgery
Study: 36438254
Drug: Oral HIV
Normalized name: HIV
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral HIV self-testing
Study: 32643543
Drug: Group hypnosis
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group hypnosis sessions (5 weekly sessions plus audio recordings)
Study: 33902621
Drug: RPH-104 80
Normalized name: RPH-104
DrugBank: Goflikicept (DB16396)
Approvals — FDA: no, EMA: no, PMDA: no
Description: RPH-104 80 mg
Study: 33902621
Drug: RPH-104 160
Normalized name: RPH-104
DrugBank: Goflikicept (DB16396)
Approvals — FDA: no, EMA: no, PMDA: no
Description: RPH-104 160 mg
Study: 34802107
Drug: Barbed reposition
Approvals — FDA: no, EMA: no, PMDA: no
Description: Barbed reposition pharyngoplasty (BRP) surgery with preoperative drug-induced sleep endoscopy (DISE) evaluation (Group B)
Study: 34802107
Drug: Barbed reposition
Approvals — FDA: no, EMA: no, PMDA: no
Description: Barbed reposition pharyngoplasty (BRP) surgery without preoperative drug-induced sleep endoscopy (DISE) evaluation (Group A)
Study: 34324016
Drug: Fluoroscopy-guided injection
Normalized name: Autologous CD34+ cells isolated from mobilised peripheral blood by positive selection, modified by CRISPR/Cas9 (clustered regularly interspaced short palindromic repeats/CRISPR-associated protein 9) mediated gene editing consisting of a guide RNA (gRNA)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluoroscopy-guided injection
Study: 32914911
Drug: Non-image-guided injection
Normalized name: Tavist Non-Sedating
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-image-guided injection
Study: 35302631
Drug: Treatment drugs
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment drugs
Study: 33957337
Drug: Topical estradiol
Normalized name: estradiol Topical Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical estradiol (2 mg)
Study: 33957337
Drug: Belief of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Belief of receiving estradiol treatment
Study: 34627809
Drug: 0.05% atropine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.05% atropine continued treatment
Study: 34627809
Drug: 0.025% atropine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.025% atropine continued treatment
Study: 34627809
Drug: 0.01% atropine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.01% atropine continued treatment
Study: 34627809
Drug: Overall continued
Approvals — FDA: no, EMA: no, PMDA: no
Description: Overall continued treatment
Study: 36401274
Drug: SVV-based goal-directed
Normalized name: direct blue 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: SVV-based goal-directed fluid therapy (GDFT) with 3 ml/kg hydroxyethyl starch solution when SVV > 15% for more than 5 min intraoperatively
Study: 32916308
Drug: Concurrent chemoradiotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Concurrent chemoradiotherapy (CRT) with pembrolizumab
Study: 34328366
Drug: Early rhythm
Normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Early rhythm control therapy (ERC; using antiarrhythmic drugs or catheter ablation)
Study: 34328366
Drug: Usual care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Usual care (allowing rhythm control therapy to improve symptoms)
Study: 34328366
Drug: Early rhythm
Normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Early rhythm control therapy (ERC)
Study: 32354780
Drug: Melatonin 4
Normalized name: vit B/folic acid/calcium/soy xt/black cohosh xt/melatonin 400 mcg-125 mg-62 mg-40 mg (day)/175 mg-62 mg-1 mg (night) ORAL CAPSULE, SEQUENTIAL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Melatonin 4 mg
Study: 36287306
Drug: Berdazimer gel,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Berdazimer gel, 10.3%, applied once daily for 12 weeks
Study: 35246028
Drug: Aspirin group
Normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aspirin group (n=11)
Study: 35246028
Drug: Both groups
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both groups (Aspirin and DAPT)
Study: 35770120
Drug: Norepinephrine therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Norepinephrine therapy (0.050.5 μg∗kg‐1/min)
Study: 35770120
Drug: Conventional treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional treatment (115 μg/kg∗min dopamine)
Study: 35770120
Drug: Norepinephrine therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Norepinephrine therapy
Study: 32795562
Drug: Dual-task training
Normalized name: Tums Dual Action
DrugBank: Alginic acid (DB13518)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dual-task training (20 sessions, 1 hour each, twice a week)
Study: 32795562
Drug: Single-task training
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single-task training (20 sessions, 1 hour each, twice a week)
Study: 34670042
Drug: 1200 mg
Normalized name: aspirin 1200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1200 mg lanifibranor
Study: 34670042
Drug: 800 mg
Normalized name: bran 800 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 800 mg lanifibranor
Study: 35941584
Drug: Canagliflozin treatment
Normalized name: Canagliflozin
DrugBank: Canagliflozin (DB08907)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Canagliflozin treatment for 24 weeks
Study: 35941584
Drug: Glimepiride treatment
Normalized name: Glimepiride
DrugBank: Glimepiride (DB00222)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Glimepiride treatment for 24 weeks
Study: 33236103
Drug: Both treatments
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both treatments (DR-HC and TID-HC)
Study: 32912140
Drug: Adherence to
Normalized name: Wong To Yick
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adherence to WHO guidelines for antibiotic treatment
Study: 32859392
Drug: Heparin-bonded polytetrafluoroethylene
Normalized name: polytetrafluoroethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heparin-bonded polytetrafluoroethylene
Study: 33783339
Drug: Training program
Approvals — FDA: no, EMA: no, PMDA: no
Description: Training program for PEP prescription guidelines
Study: 35927740
Drug: Customized adherence
Normalized name: sulfur
DrugBank: Octasulfur (DB09353)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Customized adherence enhancement (CAE) delivered via telehealth communications, comprising up to four standard treatment modules: Psychoeducation, Communication with Providers, Medication Routines, and Modified Motivational Interviewing.
Study: 33010046
Drug: Pharmacokinetically guided
Normalized name: Autologous CD34+ cells isolated from mobilised peripheral blood by positive selection, modified by CRISPR/Cas9 (clustered regularly interspaced short palindromic repeats/CRISPR-associated protein 9) mediated gene editing consisting of a guide RNA (gRNA)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmacokinetically guided dosing of pazopanib
Study: 34617261
Drug: Allopurinol 20
Normalized name: allopurinol 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Allopurinol 20 mg/kg (first dose), 10 mg/kg (second dose if undergoing therapeutic hypothermia)
Study: 39773886
Drug: Aspirin-clopidogrel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin-clopidogrel
Study: 34304604
Drug: Aspirin-dipyridamole
Normalized name: aspirin-dipyridamole
DrugBank: Dipyridamole (DB00975)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aspirin-dipyridamole
Study: 32645078
Drug: Belief that
Normalized name: Ora Relief
Approvals — FDA: no, EMA: no, PMDA: no
Description: Belief that HBV vaccine was safe
Study: 32127214
Drug: Extracorporeal Shock
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Extracorporeal Shock Wave Therapy
Study: 36255730
Drug: Gram stain-guided
Normalized name: fluorexon stain
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gram stain-guided initial antibiotic therapy
Study: 34107720
Drug: Combined supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined supplementation with vitamin D (40,000 IU) and omega-3 fatty acids (8,000 mg) twice a day for 6 weeks
Study: 32229541
Drug: Pulmonary tele-rehabilitation
Normalized name: Lobaria pulmonaria extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pulmonary tele-rehabilitation (PTR) for 10 weeks (60 min, three times weekly)
Study: 32229541
Drug: Conventional pulmonary
Normalized name: Lobaria pulmonaria extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional pulmonary rehabilitation (PR) for 10 weeks (90 min, two times weekly)
Study: 33369253
Drug: Sham treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sham treatment (C)
Study: 32955455
Drug: Mobile health
Normalized name: Healthy Mama
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mobile health (mHealth): entertaining educational audio capsules and voice immunization reminders via mobile phone
Study: 36066319
Drug: Restrictive transfusion
Normalized name: Pinus spp. wood destructive distillate
DrugBank: Pine tar (DB15840)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Restrictive transfusion strategy (RBCs transfused when hemoglobin <7.5 g/dl)
Study: 36066319
Drug: Liberal transfusion
Normalized name: dextromethorphan
DrugBank: Dextromethorphan (DB00514)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Liberal transfusion strategy (transfusion triggers: <9.5 g/L intraoperatively, <9.5 g/L in intensive care, <8.5 g/dl on the ward)
Study: 34418670
Drug: NMES +
Approvals — FDA: no, EMA: no, PMDA: no
Description: NMES + exercise therapy
Study: 33402575
Drug: Topical Betamethasone
Normalized name: betamethasone Topical Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical Betamethasone Valerate 0.1% cream, applied twice daily during radiotherapy/chemo-radiotherapy
Study: 35089205
Drug: Antibiotic cement
Normalized name: Cement
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antibiotic cement coating group
Study: 33832490
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy of periodontal curettage and root planing
Study: 35385050
Drug: Canakinumab (50,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Canakinumab (50, 150, and 300 mg once every 3 months)
Study: 35954937
Drug: Seawater hydration
Normalized name: Chloral Hydrate
DrugBank: Chloral hydrate (DB01563)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Seawater hydration (Totum SPORT, Laboratories Quinton International, S.L., Valencia, Spain)
Study: 33533155
Drug: 2.5% agarose
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.5% agarose gel
Study: 33533155
Drug: NASHA-L
Normalized name: L-377202
DrugBank: L-377202 (DB19022)
Approvals — FDA: no, EMA: no, PMDA: no
Description: NASHA-L
Study: 33533155
Drug: 2.5% agarose
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.5% agarose gel and NASHA-L
Study: 32853585
Drug: Ipilimumab group
Normalized name: Ipilimumab
DrugBank: Ipilimumab (DB06186)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Ipilimumab group (brentuximab vedotin 1.8 mg/kg with ipilimumab 1 mg/kg or 3 mg/kg)
Study: 32853585
Drug: Nivolumab group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nivolumab group (brentuximab vedotin 1.2 mg/kg or 1.8 mg/kg with nivolumab 3 mg/kg)
Study: 32853585
Drug: Triplet therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triplet therapy group (brentuximab vedotin 1.2 mg/kg or 1.8 mg/kg with nivolumab 3 mg/kg and ipilimumab 1 mg/kg)
Study: 34112001
Drug: Taurolock‐hep500™ as
Approvals — FDA: no, EMA: no, PMDA: no
Description: Taurolock‐hep500™ as a catheter lock solution
Study: 34112001
Drug: Unfractionated heparin
Normalized name: Unfractionated heparin
DrugBank: Heparin (DB01109)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Unfractionated heparin as a catheter lock solution
Study: 34656191
Drug: SET‐C (Social
Approvals — FDA: no, EMA: no, PMDA: no
Description: SET‐C (Social Effectiveness Therapy for Children)
Study: 32256897
Drug: Medication review
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medication review service (delivered by clinical pharmacists)
Study: 32256897
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no medication review service)
Study: 34289820
Drug: Extensively hydrolyzed
Normalized name: collagen, hydrolyzed
Approvals — FDA: no, EMA: no, PMDA: no
Description: Extensively hydrolyzed formula (EHF) at 2.4 g protein/100 kcal
Study: 34289820
Drug: Amino acid-based
Normalized name: silk amino acids
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amino acid-based formula (AAF) at 2.4 g total protein equivalents/100 kcal
Study: 34289820
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (EH casein formula at 2.8 g protein/100 kcal)